Wahedna I, Wisniewski A S, Tattersfield A E
Respiratory Medicine Unit, City Hospital, Nottingham.
Br J Clin Pharmacol. 1991 Oct;32(4):512-5. doi: 10.1111/j.1365-2125.1991.tb03941.x.
We have studied the effect of RG 12525, an oral leukotriene D4 (LTD4) antagonist, on LTD4-induced bronchoconstriction in eight male subjects with mild asthma (baseline FEV1 greater than 80% predicted) in a double-blind, placebo-controlled fashion. RG 12525 800 mg displaced the dose-response curve for LTD4 to the right. The mean (95% confidence intervals) difference in log PC20FEV1 following RG 12525 and placebo was 2.88 (1.61, 4.17) doubling doses of LTD4 (P less than 0.01), a 7.5 fold difference. We conclude that RG 12525 when administered orally is an effective LTD4 antagonist in subjects with mild asthma.
我们采用双盲、安慰剂对照的方式,研究了口服白三烯D4(LTD4)拮抗剂RG 12525对8名轻度哮喘男性受试者(基线第一秒用力呼气容积[FEV1]大于预测值的80%)中LTD4诱导的支气管收缩的影响。800毫克的RG 12525使LTD4的剂量反应曲线右移。服用RG 12525和安慰剂后,log PC20FEV1的平均(95%置信区间)差异为2.88(1.61,4.17)个LTD4加倍剂量(P<0.01),相差7.5倍。我们得出结论,口服RG 12525对轻度哮喘受试者是一种有效的LTD4拮抗剂。